The global clinical trials market is projected to grow from USD 57.8 billion in 2026 to USD 113.7 billion by 2036, registering a compound annual growth rate (CAGR) of 7.0% during the forecast period, according to Future Market Insights (FMI). The market was valued at USD 54.0 billion in 2025, with the forecast indicating an additional revenue opportunity of USD 55.9 billion between 2026 and 2036.

Growth is being supported by expanding biopharmaceutical research pipelines, increasing reliance on outsourced clinical operations and demand for specialized trial execution. Oncology and immuno-oncology programmes, cell therapies, antibody-drug conjugates and metabolic drug development are increasing the complexity of clinical research. Sponsors are consequently seeking CRO partners with international investigator networks, biomarker testing capabilities and integrated data-management infrastructure.

👉 Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends:
https://www.futuremarketinsights.com/reports/sample/rep-gb-384

The Short Version

· Market outlook: USD 57.8 billion in 2026, rising to USD 113.7 billion by 2036.

· Growth rate: 7.0% CAGR over the 2026–2036 forecast period.

· Leading trial phase: Phase III multi-center confirmatory studies, with a 52.0% share in 2026.

· Leading therapeutic area: Oncology and immuno-oncology, accounting for 44.0% of 2026 demand.

· Dominant service model: Outsourced Contract Research Organization (CRO) services, representing 68.0% of the service-model segment.

· Fastest-growing country: South Korea, forecast to expand at a 7.7% CAGR.

Three Numbers That Matter

USD 113.7 billion: The projected global clinical trials market value by 2036.

68.0%: The estimated 2026 share of outsourced CRO models, reflecting sponsors’ preference for external clinical operations and global site-management capabilities.

49.0%: The projected 2026 share of biomarker-stratified and adaptive protocol trials within the trial-design category, highlighting the growing role of precision-led research.

What Is Driving the Clinical Trials Market?

The expansion of precision medicine is increasing demand for clinical studies that require specialized patient recruitment, biomarker screening and long-term monitoring. Oncology and immuno-oncology account for 44.0% of therapeutic-area demand in 2026, supported by research involving antibody-drug conjugates, cell therapies and bispecific medicines.

The growing complexity of these programmes is encouraging pharmaceutical and biotechnology sponsors to outsource clinical development activities. CROs provide access to established investigator networks, regulatory expertise, site monitoring, patient recruitment and clinical data-management capabilities. FMI estimates that outsourced CRO models account for 68.0% of service-model demand in 2026.

Decentralized and hybrid trial approaches are also creating opportunities to improve patient participation. Remote consent, telehealth oversight, direct-to-patient investigational drug delivery and local laboratory services can help sponsors reach participants beyond major academic medical centres. However, recruitment bottlenecks, staffing shortages, high screening-failure rates and cross-border data-privacy requirements remain important operational challenges.

Where Growth Is Strongest

FMI identifies South Korea as the fastest-growing national market, with a projected 7.7% CAGR through 2036. Its tertiary hospital infrastructure, electronic medical record capabilities and support for vaccine and cell-therapy research are contributing to its clinical research outlook.

The United States follows at 7.4%, supported by its biopharmaceutical research base, oncology site networks and regulatory initiatives. Switzerland is projected to grow at 7.3%, while Canada is expected to register 7.2% growth.

Other country forecasts include:

· United Kingdom: 7.0% CAGR

· Germany: 6.8% CAGR

· Japan: 6.7% CAGR

· France: 6.2% CAGR

These markets offer different strategic advantages, ranging from established biopharmaceutical research ecosystems to regulatory modernization and specialized hospital-based clinical networks.

Segment Outlook: Phase III, Oncology and Outsourced Research

Phase III multi-center confirmatory trials are projected to hold 52.0% of trial-phase demand in 2026. These studies require large patient cohorts, multi-country site coordination and extensive efficacy and safety evidence to support regulatory submissions.

Oncology and immuno-oncology represent 44.0% of therapeutic-area demand. The segment's importance reflects investment in targeted cancer therapies and complex treatment modalities that require biomarker screening and specialized monitoring.

Within service models, outsourced CRO services hold a 68.0% share. Sponsors are using external providers to access global clinical infrastructure while managing internal operating costs. Biomarker-stratified and adaptive protocol trials account for 49.0% of trial-design demand, while large and mid-cap biopharmaceutical sponsors represent 56.0% of sponsor-entity demand in 2026.

Competitive Landscape: Key Companies

The clinical trials market includes global CROs, integrated laboratory providers and specialized clinical research organizations. Companies profiled by FMI include:

· IQVIA Holdings Inc.

· ICON plc

· Laboratory Corporation of America Holdings (Labcorp)

· Thermo Fisher Scientific Inc. (PPD)

· Syneos Health Inc.

· Medpace Holdings Inc.

· Charles River Laboratories International Inc.

· Parexel International Corporation

· Fortrea Holdings Inc.

· WuXi AppTec Co., Ltd.

Recent developments highlighted in the report include Syneos Health's October 2026 partnership with Optum to advance an adaptive clinical development model, IQVIA's October 2026 launch of its Life Science Models, and ICON's July 2026 collaboration with Anthropic to introduce AI across clinical trial operations.

These developments illustrate how competition is extending beyond conventional site management toward integrated data, artificial intelligence, patient recruitment and clinical workflow capabilities.

Access The Full Report: https://www.futuremarketinsights.com/reports/clinical-trials-market

Analyst Perspective

“Biopharma sponsors no longer select contract research organizations solely on per-monitor hourly rates; they buy predictable first-patient-in timelines and biomarker-screened enrollment speed. CROs that pair real-world electronic health record patient matching with integrated central laboratories will capture dominant Phase III registration awards.”

— Anurag Sharma, Principal Consultant, Future Market Insights.

Strategic Priorities for Market Participants

CROs and clinical research service providers can strengthen their market position by investing in global site networks, central laboratory capabilities and integrated data-management platforms. Providers that support biomarker-led recruitment and adaptive trial execution may be better positioned to serve increasingly complex development programmes.

Sponsors should also assess recruitment performance, geographic coverage, regulatory expertise and the ability to coordinate multiple service providers when selecting CRO partners. While decentralized models can broaden patient access, execution depends on suitable technology, clear oversight responsibilities and reliable local clinical infrastructure.

Related Reports:

· Medical Mask Market - https://www.futuremarketinsights.com/reports/medical-mask-market

· Immunomodulator Market - https://www.futuremarketinsights.com/reports/immunomodulator-market

· Pharmacy Automation System Market - https://www.futuremarketinsights.com/reports/pharmacy-automation-systems-market-092017

About Future Market Insights (FMI)

Future Market Insights (FMI) is a market intelligence and consulting organization providing research, analysis and strategic insights across industries. FMI supports business decision-makers with market forecasts, competitive assessments and industry perspectives to help evaluate emerging opportunities and changing market dynamics.

Media and Business Enquiries

Email: [email protected]
Phone: +1 347 918 3531
Website: https://www.futuremarketinsights.com/